Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

While they share similarities, there are differences, particularly between the drugs semaglutide and tirzepatide.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...